Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy

R Idilman

Article Text

Letter

Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

R Idilman was supported by the Turkish Academy of Sciences, in the framework of the Young Scientist Award Program (EA-TUBA-GEBIP/2001-1-1).
Conflict of interest: None declared.

Linked Articles

Hepatitis
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

C-K Hui W W W Cheung W-Y Au A K W Lie H-Y Zhang Y-H Yueng B C Y Wong N Leung Y-L Kwong R Liang G K K Lau
Gut 2005; 54 1597-1603 Published Online First: 06 Jul 2005. doi: 10.1136/gut.2005.070763

Log in using your username and password

Main menu

Log in using your username and password

You are here

Statistics from Altmetric.com

Request Permissions

Footnotes

Linked Articles

Read the full text or download the PDF:

Log in using your username and password

Read the full text or download the PDF:

Log in using your username and password